Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution
Dhon Roméo Makanga(Centre National de la Recherche Scientifique), Christelle Retière(Centre National de la Recherche Scientifique), Anne Cesbron(Services déconcentrés d'appui à la recherche Pays de la Loire), Patrice Chevallier(Hotel Dieu Hospital), Katia Gagne(Inserm), Alice Garnier, Nolwenn Legrand(Centre National de la Recherche Scientifique), Marie C. Béné(Centre Hospitalier Universitaire de Nantes), Catherine Willem(Centre National de la Recherche Scientifique), Amandine Le Bourgeois, Thierry Guillaume(Centre National de la Recherche Scientifique), Ketevan Gendzekhadze(City Of Hope National Medical Center), Pierre Péterlin(Hotel Dieu Hospital)
Cited by 29
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
|Blood|2013|358
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2016|347